The U.S. Food and Drug Administration (FDA) has processed Abbreviated New Drug Application (ANDA) number ANDA205757 submitted by Pharmascience Inc. The submission was classified under a standard review priority and recorded a status of "TA" (tentative approval) on February 15, 2019. No additional details about the product or approval conditions were provided in the filing information.
This entry reflects the regulatory milestone for the generic drug application as reported by the FDA's drug approval records.
Actualizaciones regulatorias11 sept 2026•1 min de lectura
FDA Grants ANDA Approval for PHARMASCIENCE INC (ANDA205757)
The FDA issued a standard review tentative approval (TA) for ANDA205757 submitted by Pharmascience Inc., status dated Feb 15, 2019.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración